NCT01393184View on ClinicalTrials.gov

Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN

PHASE2UnknownINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

March 31, 2013

Conditions
SCCHN
Interventions
DRUG

Nimotuzumab and Radiotherapy

Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT

Sponsors
All Listed Sponsors
collaborator

Biotech Pharmaceutical Co., Ltd.

OTHER

lead

Peking University

OTHER